Research programme: large molecules - Zosano Pharma

Drug Profile

Research programme: large molecules - Zosano Pharma

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Zosano Pharma
  • Class Ciclosporins; Growth factors; Growth hormones; Monoclonal antibodies; Oligonucleotides; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Growth hormone releasing factor antagonists; Immunosuppressants; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Growth disorders; Type 2 diabetes mellitus; Unspecified

Most Recent Events

  • 29 Sep 2015 Preclinical trials in Growth disorders in USA (Transdermal)
  • 29 Sep 2015 Preclinical trials in Undefined indication in USA (Transdermal)
  • 29 Sep 2015 Preclinical trials in Type-2 diabetes mellitus in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top